THARIMMUNE INC(NASDAQ:THAR) stock Fundamental Analysis

Fundamental Rating

Overall THAR gets a fundamental rating of 2 out of 10. We evaluated THAR against 572 industry peers in the Biotechnology industry. While THAR seems to be doing ok healthwise, there are quite some concerns on its profitability. THAR is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year THAR has reported negative net income.

In the past year THAR has reported a negative cash flow from operations.

THAR had negative earnings in each of the past 5 years.

THAR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of THAR (-206.63%) is worse than 90.97% of its industry peers.

The Return On Equity of THAR (-359.59%) is worse than 77.17% of its industry peers.

		Industry Rank	Sector Rank
ROA	-206.63%
ROE	-359.59%
ROIC	N/A

ROA(3y)-188.86%

ROA(5y)-1021.35%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

THAR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for THAR has been increased compared to 1 year ago.

There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -14.27, we must say that THAR is in the distress zone and has some risk of bankruptcy.

THAR has a worse Altman-Z score (-14.27) than 81.59% of its industry peers.

THAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-14.27

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

THAR has a Current Ratio of 2.35. This indicates that THAR is financially healthy and has no problem in meeting its short term obligations.

THAR has a Current ratio of 2.35. This is in the lower half of the industry: THAR underperforms 72.74% of its industry peers.

A Quick Ratio of 2.35 indicates that THAR has no problem at all paying its short term obligations.

THAR has a worse Quick ratio (2.35) than 71.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.35
Quick Ratio	2.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 92.41% over the past year.

EPS 1Y (TTM)92.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%93.79%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, THAR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y99.91%

EPS Next 2Y41.4%

EPS Next 3Y25.98%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

THAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THAR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

THAR's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.4%

EPS Next 3Y25.98%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for THAR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THARIMMUNE INC

NASDAQ:THAR (1/22/2025, 2:05:03 PM)

2.01

-0.1 (-4.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-05 2024-08-05/bmo

Earnings (Next)N/A N/A

Inst Owners0.86%

Inst Owner Change41.23%

Ins Owners1.88%

Ins Owner Change78.11%

Market Cap2.99M

Analysts43.33

Price TargetN/A

Short Float %4.17%

Short Ratio0.04

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.99
P/tB	0.99
EV/EBITDA	N/A

EPS(TTM)-198.19

EYN/A

EPS(NY)-0.12

Fwd EYN/A

FCF(TTM)-6.23

FCFYN/A

OCF(TTM)-6.23

OCFYN/A

SpS0

BVpS2.03

TBVpS2.03

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-206.63%
ROE	-359.59%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-188.86%

ROA(5y)-1021.35%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.35
Quick Ratio	2.35
Altman-Z	-14.27

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)92.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%93.79%

EPS Next Y99.91%

EPS Next 2Y41.4%

EPS Next 3Y25.98%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-27.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-63.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-63.65%

OCF growth 3YN/A

OCF growth 5YN/A

THARIMMUNE INC (THAR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens